Patient preference & outcomes
What patients actually trade off, quantified, plus the PRO or COA scaffolding to carry it.
Shortlist it, send it over — we come back with the shape we'd actually recommend.
What patient preference & outcomes actually is.
What patients actually trade off, quantified, paired with the PRO or COA selection or design that anchors it in label and value-story conversations. Quant and qual, with the rigour the regulator and the agency will accept.
Built for medical, access and HEOR teams where the patient-preference evidence has to defend a label claim, a value-story argument or a model input, not decorate a slide.
- Patient preference study report
- Quantified trade-off structure with confidence intervals
- PRO or COA selection or design recommendation
- Implications for label, value story and model inputs
- Working read-out for medical, access and HEOR
Add the pieces you'd want and we'll build a shortlist you can review, reorder and send over. No pricing wall, no commitment — we come back with what we'd actually recommend, including anything you don't need.
Approach, modules, delivery.
Move through the tabs to see how the work runs, what it's made of and what lands at the end.
Inputs
- Therapy-area context and target patient population
- Candidate PRO / COA instruments (existing and validated)
- Qualitative concept-elicitation interviews with patients and carers
- Quantitative discrete-choice experiment (DCE) design parameters
Method
Combine qualitative concept-elicitation with a quantitative discrete-choice experiment to quantify what patients actually trade off, then pair with the PRO / COA selection (or de-novo design) that anchors those preferences in label, value story and HTA conversations. Outputs are publishable and FDA / EMA-aware (PFDD, IMI PREFER patterns).
Assumptions
- Patient access for primary research is feasible inside the engagement window and ethics framework.
- Sample sizes for the DCE are sufficient to detect the trade-offs of interest (typically n=200–400 per market).
Limitations
- Preference findings are population-level, individual patient choices vary.
- PRO / COA selection has to be made within the constraint of what's been validated for the indication; bespoke instrument design adds 9–12 months.
Think this belongs in your scope?
Add it alongside anything else that fits, then send the shortlist over. We'll reply with the shape we'd recommend — sequence included, and the parts we think you can skip.
Build what comes next.
Whether you need growth, answers or capability, VISFO helps you move earlier and faster.